

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	09/976,249
Filing Date	October 15, 2001
First Named Inventor	Giorgio ATTARDO
Group Art Unit	1654
Examiner Name	Michael V. Meller
Attorney Docket Number	PHARMA-123

U.S. PATENT DOCUMENTS

[illegible]

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature


Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number 09/976,249
Filing Date October 15, 2001
First Named Inventor Giorgio ATTARDO
Group Art Unit 1654
Examiner Name Michael V. Meller
Attorney Docket Number PHARMA-123

RECEIVED

MAR 21 2003

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Mm	4	K.L. Grove et al, "Beta-L-(-)-Dioxolane Cytidine As A Potent Compound For The Treatment Of Cancer", Nucleosides & Nucleotides, Vol. 16, No. 7-9, 1997, pp. 1229-33, XP000971189	
	5	S.A. Kadhim et al, "Potent Antitumor Activity Of A Novel Nucleoside Analogue", Cancer Research, Vol. 57, November 1, 1997, pp. 4803-4810, XP000971188	
	6	Chemical Abstracts, Vol. 133, No. 5, 2000, Columbus, Ohio, US; abstract no. 53116p, Kukhanova, M.: "Excision Of Beta-L-And Beta-D-Nucleotide Analogs From DNA By P53 Protein", pg. 17; column 1; XP002199460, abstract & Nucleosides, Nucleotides Nucleic Acids, Vol. 19; No. 1-2, 2000, pp. 435-446, USA	
	7	K. Grove et al, "Anticancer Activity Of Beta-L-Dioxolane-Cytidine", Cancer Research., Vol. 55, July 15, 1995, pp. 3008-11, XP002199458, American Association For Cancer Research, Baltimore, MD., US	
	8	S.A. Rabbani et al, "Effect of Nucleoside Analogue BCH-4556 On Prostate Cancer Growth And Metastases", Cancer Research, Vol. 58, August 1, 1998, pp. 3461-5, XP002199459, American Association For Cancer Research, Baltimore, MD, US	

Examiner Signature

Date Considered

6/2/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.